Should You Buy Adaptive Biotechnologies Corporation Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Adaptive Biotechnologies Corporation (ADPT) carries a solid Quality of Company rating of 7.2/10. Trading at $26.44, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 0 of 0 CirclFi valuation models project upside for Adaptive Biotechnologies Corporation (ADPT) at $26.44 — the models are evenly split, with a Quality Score of 7.2/10 and Value-Trap risk of 25/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Adaptive Biotechnologies Corporation (ADPT) in 2026?
What Is the Bull Case vs the Bear Case for Adaptive Biotechnologies Corporation (ADPT)?
| Bull case | Bear case |
|---|---|
| No active model projects meaningful upside for ADPT at $26.44. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | No active model flags significant downside for ADPT. The low Value Trap score paints a constructive picture. |
How Does ADPT Compare to Its Diagnostics & Research Peers?
Valuation data pages: CDNA · GH · TWST · FLGT · CSTL · CRL · BDSX · FUNI · DHR · IDXX · MEDP
Which Other Stocks Score Like ADPT on Quality?
Closest companies to ADPT’s Quality of Company score of 7.2/10, across all industries.
- LFST — LifeStance Health Group, Inc. (QOC 7.2) · analysis
- NMRK — Newmark Group, Inc. (QOC 7.2) · analysis
- AFRM — Affirm Holdings, Inc. (QOC 7.2) · analysis
- HYNE — Hoyne Bancorp, Inc. (QOC 7.2) · analysis
- UTL — Unitil Corporation (QOC 7.2) · analysis
- SVV — Savers Value Village, Inc. (QOC 7.2) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Adaptive Biotechnologies Corporation (ADPT) Worth Buying in 2026?
Adaptive Biotechnologies Corporation currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.
These are quantitative model outputs, not investment recommendations. Adaptive Biotechnologies Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ADPT Stock?
Should I buy ADPT stock right now?
Based on CirclFi's multi-model analysis, 0 of 0 models see upside for ADPT at $26.44. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Adaptive Biotechnologies Corporation?
Key risks include: limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Diagnostics & Research companies. Always diversify and consult a financial advisor.
How does ADPT compare to its competitors?
Among Diagnostics & Research peers, ADPT holds a Quality Score of 7.2/10. Comparable companies include CDNA (QOC 7.3), GH (QOC 7.0), TWST (QOC 7.4). The relative ranking helps investors identify whether ADPT offers better fundamental quality than alternatives in the same sector.
Is ADPT a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ADPT's Quality Score of 7.2/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy ADPT at?
CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ADPT.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad